[ad_1]
ZURICH (Reuters) – Roche announced Monday that it would buy out Spark Therapeutics as part of a deal valued at $ 4.3 billion ($ 3.3 billion) while the Swiss drug maker built his hemophilia portfolio and seeks to keep pace with gene therapy with competitors like Novartis.
Roche will buy Spark in the United States for $ 114.50 per share, a premium of about 122% over Spark's closing price on February 22, the Swiss company said in a statement.
(Report by John Miller, edited by Thomas Seythal)
Source link
